CMSC 2021 - Neurology Advisor neurologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neurologyadvisor.com Daily Mail and Mail on Sunday newspapers.
Decreased COVID Antibody Response in MS Patients Taking Ocrelizumab medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in African American patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) than in white patients, a study suggests.
“While previous research has shown that this type of [into-the-vein] therapy is effective for people with those diseases, we also know that Black people tend to have more severe courses of MS,” llya Kister, MD, said in a press release. Kister, of the NYU Grossman School of Medicine in New York, is the study’s senior author and a fellow of the American Academy of Neurology.
Common MS Treatment Wears Off More Quickly in Black Patients medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.